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Summary
‘Creating an innovative department’ as an objective implies further improvements in organization, function, and progression of a surgical unit
active in patient care, research, and education. It is of prime importance to stress here the mutual benefits of patient care, research (the basis
for future patient care) and education (the channel for training health care professionals in future patient care). Neither innovation (from latin
innovare: to renew, revive) nor creation (from latin creare: to make, produce) is something that will fall from heaven without effort any time
soon. Hence, a pro-active attitude towards progress is indicated. This requires searching for new ideas, allocation of resources, finding allies,
getting focussed, and being persistent. One word says it all: WORK!
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Tremendous success, exaggerated safety concerns, over-
regulation, and lack of interest among other developments
have led to a situation in many departments, where
enthusiasm has evaporated, stagnation is taking over, and
worse, regression has arrived. As a matter of fact,
percutaneous procedures have seen a much stronger devel-
opment (2.3 times higher caseload in Switzerland by now)
than traditional coronary artery bypass grafting [1], and this
despite proven superior results with arterial conduits [2],
and the efforts made for reduction of pump related events
with off-pump techniques [3].2. General developments
However, such a development is not specific for the
cardio-vascular field or medicine, and is rather the rule for
many fields. Nowadays, endoscopes are used routinely for
inspection of the combustion chamber in Otto or Diesel
engines, despite the fact that the surfaces of interest can
also be visualized if the cylinder heads are removed.
Likewise, obstructed or leaking drain pipes can be inspected
and even repaired with robotic systems, thus avoiding
major road works and the consecutive traffic jam. Neither1567-4258/$ - see front matter q 2004 Published by Elsevier B.V.
doi:10.1016/j.ejctsup.2004.11.022
* Presented at the EACTS Symposium for the Future of Cardiac Surgery,
Frankfurt, Germany, July 1–2, 2004.
*Tel.: C41 21 314 22 80; fax: C41 21 314 22 79.
E-mail address: ludwig.von-segesser@chuv.hospvd.ch
URL: www.cardiovasc.net.the construction companies, nor manufacturers of earth
moving equipment (e.g. Caterpillar, Liebherr, Komatsu) nor
car repair shops have disappeared. What has changed are
mobility and speed of communication, which in turn require
accelerated search of new opportunities and the correspond-
ing adaptation of both human resources and infrastructure.3. Specific developments
Not all surgical disciplines have managed such changes
with equal success, but some have done this very well. The
urologists, who emerged from general surgery have success-
fully managed the transition from open surgery to endo-
scopic treatments and even percutaneous procedures. But
not only that, the urologists have also been able to maintain
a significant stake in the entire value chain from diagnostics
(e.g. ultrasound), to patient work-up (e.g. cystoscopy,
ureteroscopy, biopsy, pyelography), treatment (e.g. trans-
urethral resection, shock wave lithotrypsy), and follow-up
(e.g. instillation of anti-mitotic drugs).
We are far away from having solved all cardio-vascular and
pulmonary problems, and therefore, thoracic and cardio-
vascular surgery has a huge potential for further develop-
ment, provided we are willing to stay involved. Although the
main characteristic of surgery is ‘manual operation’ as the
original Greek term translates to, its enhancement with
technology multiplies its potential (e.g. automated CPR,
CPS, VAD, TAH). Of course, there are not only technological
hurdles to overcome in order to make significant progress.
A number of concerns in our context and potential answers
are listed in Table 1.European Journal of Cardio-thoracic Surgery 26 (2004) S78–S81www.elsevier.com/locate/ejcts
Table 1
Food for thought proposed at the Symposium for the Future
† Products have a live (birth, growth, death)
The same holds true for treatment strategies and procedures (e.g. MIDCAB)
† Change is everywhere
Change implies problems and opportunities (e.g. merging programs)
† Innovation versus stagnation
Our attitude is our responsibility
† Activities should include clinical work, research, and teaching
Resources have to be allocated accordingly
† Regulations kill innovation
Organizations should refrain from ruling everything
† Working hours should be unlimited
Competition cannot be forbidden
† Off-hours science clubs may be an answer
If golf is ok, what about virtual perfusion
† Growth can be qualitative and quantitative
Not all specialities have abandoned diagnostics
† Volume can be achieved by specialization or generalization
Bentall procedure, mini-root aortic valve replacement, valve preserving
aortic root repair, Ross procedure, and arterial switch are all the same
† Cooperations can be institutional, regional, national and international
There are no limits to tele-consulting, tele-medicine, and tele-monitoring
between doctors, scientists, patients, etc.
Table 4
View of the working group: opportunities
† Develop new activities
† Cooperate with other societies
Table 3
View of the working group: potential threats
† Loss of access to patients
† Loss of income
† Loss of support for research
† Loss of training opportunities
† Loss of .
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During this meeting, the working group in charge
‘Creating Innovative Departments’ devised a series of
statements, which are displayed in Tables 2–5. With regard
to the status quo, increasing competition appeared to be of
major concern for Western Europe, due to a still increasing
number of thoracic and cardio-vascular surgical units and a
decreasing number of cases (Table 2), surgical cases of
course. As we have seen earlier, the number of patients
treated for coronary artery disease is still increasing, but in
other departments. Likewise, there is still growth in surgical
units in Eastern Europe and even more so in other
geographical zones. Many participants, perceived the
developments in Western Europe just described as a major
threat at the level of the units, as well as at the level of the
individuals involved (Table 3). However, a number of
opportunities were also identified (Table 4). On top of the
search for improved and new activities, ranks the pivotal
role of the European Association for Cardio-thoracic Surgery
as an instrument for promotion of big trials showing the true
value of surgical approaches. Table 5 lists the required
actions for strengthening thoracic and cardio-vascular
surgery in general as well as its individual units.† Make EACTS meeting the largest event
† Create EACTS Research Center for big trials
Table 5
View of the working group: actions5. Comment
It has to be mentioned here, that the development and
implementation of new ideas, new procedures, new tech-
nology, and new solutions needs not only an open mind [4],Table 2
View of the working group: status quo
† Number of centers increase
† Number of cases decrease
† More competition resultsbut at least as much perseverance to reach the so-called
‘break through’. Personally, I am increasingly convinced that
the discovery of a new procedure, or a major break-through
by a stroke of luck is the very, very exception, and that the
main steps forwards have usually been achieved on the basis
of long and hard work. This is by no means a new discovery
but has always been like that, as the following few examples
may illustrate.
It took the polish astronomer Copernicus a long time,
perhaps 30 years [5], to produce and publish in 1543 the
epoch-making Rinensis de revulutionibus orbium coelestium
[6] describing the planetary helio-centric system, and
even more time was necessary to have his cosmology
accepted [7].
A personality much closer to our activities is certainly
Vincent L. Gott, who made pivotal contributions to the
development of cardio-vascular implants produced from
synthetic materials with improved thromboresistance [8].
Although he describes a series of serendipitous events that
lead the way to bond heparin, using a coating of graphite-
carbon and benzalkonium-chloride, it was the fact that HE
was WORKING in this field, that made his discoveries
possible. Again it took about 30 years from the description
of the principles in the 1960s [9] to ubiquitous clinical
application: heparin coatings for cardiopulmonary bypass
components [10], catheters, as well as assist devices, or
carbon coatings for prosthetic heart valves.
The development of disruptive technology is a dream,
which haunts quite some people as pointed out by J.C.
Dvorak in his column in PC-Magazine [11]. The theory goes,
that a new cheaper technology gains some foothold,
continues to improve, and then quickly bumps the older,
once superior technology. For our field of activities we now† Search, innovate
† Restructure, optimise
† Invest
† Focus
† Network
† Communicate
† Market
Table 6
Pro-active approach in a nut-shell
Evolution Accept change
Activation Hunt for ideas
Commitment Allocate resources
Momentum Convince allies
Focus Do not get distracted
Perseverance Do not give up
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mechanical heart valve prosthesis, which does not need
anticoagulation—without luck, so far. Dvorak lists a number
of so-called disruptive technologies, which in fact are not,
like digital photography. As a matter of fact digital
photography has never been cheaper than film—and it has
been introduced in 1972, more than 30 years ago (for more:
www.pcmag.com/dvorak).
‘Creating an innovative department’ as an objective
implies further improvements in organization, function,
and progression of a surgical unit active in patient care,
research, and education. It is of prime importance to stress
here the mutual benefits of patient care, research (the
basis for future patient care) and education (the channel
for training health care professionals in future patient
care). Neither innovation (from latin innovare: to renew,
revive) nor creation (from latin creare: to make, produce)
is something that will fall from heaven without effort any
time soon. Hence, a pro-active attitude towards progress
(Table 6) is indicated. In accordance to the first book
printed ever, on the seventh day, God rested from all his
work, which he had done in creation [12]. Hence, for the
more ordinary mortals among us, there can be only one
rational approach to create innovative departments:
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Appendix. Conference discussion
Dr A. Kappetein (Rotterdam, Netherlands): I very much like the idea of
setting up a research center sponsored by the European Association, but what
we should not forget is that if you want to run a trial by the Association, it
costs a lot of money. The SynTax trial which we were talking about costs
around $20 million, and the Expedition trial costed about $80 million. So trials
are too expensive to be sponsored by the European Association. But what you
could do is, support observational studies. These are sometimes as powerful
important, as Axel Haverich pointed out, as trials. There is an interesting
study in the New England Journal of Medicine that showed that observational
studies in many instances have the same outcome, as randomized trials. We
could as the European Association, for example, support registries for Ross
operations, aortic valve replacements, new techniques in coronary surgery,
and aortic stenting, and in this way you could collect data from many centers
and you will have much more power if you publish it because you have a large
number of data.
Dr von Segesser: The Association is already sponsoring a number of
databases, and if we say, for instance, we want to know the data of, let’s say,
OPCAB on the circumflex artery, I think it should not be so difficult to have our
members fill in some forms, to collect these forms, and even pay 100 Euros per
form; 1000 patients costs 100,000 Euros. That is not impossible for an
Association like ours.
So although we know that industry-sponsored studies may bring some
money into the unit, here we are talking about if our units are going to exist,
and maybe it is worth to put in some manpower to get the data we need.
Dr Kappetein: I agree. I think every unit has some money to have a
research nurse or to set up a database, and it is not so difficult to provide data
from observational studies. That is not very costly and in that way we could
easily share these data.
Dr D. Birnbaum (Regensburg, Germany): Pieter (Pieter Kappetein), you
probably read my ideas. I just wanted to say almost the same, but I would like
to add a few things.
The aim of the Association is to support science, it is a scientific society.
Therefore I believe that the Association must find ways to support research.
Research today costs a lot of money, and I am not convinced that the
Association can pay for trials such as biostatistical powered and following all
the rules, which hold for an accepted study as standard. But there are ways
such as fund-raising, and I think this Association could have the possibility to
raise funds Europe-wide. There are even institutions who do nothing else but
fund-raising as their obligation. They share the money by raising funds for an
Association like this one.
Furthermore I believe that the Association could support data registration
in a form of either work together with an enterprise, which is able to do trials
in a professional way. They don’t want too much money, but I think a contract
with them gives the possibility to maintain qualitatively good research and to
help such an institution. Alternatively the commitment of clinical researchers
to follow the consensus for a data acquisitation should make it possible to
search for important single questions. The council should deal with these
possibilities and come to a recommendation how the Association will orient on
this need for research, research in the field of clinical studies, of trials, of
observational studies, and of registries. It is a necessity to have large
registries such that the Association has some sort of control of what is going on
in the field of clinical research. By this kind of support the initiator or study
leader will feel protected for negative judgments of negative results or of
expectances of the public if the Association stands behind such a trial.
I think that the Association needs to find ways how to support this
intention to increase research activity. Otherwise we are stuck on
individualized activities, and I think this is not good, because all sorts of
discrepancies then will continue to bias these studies.
Mr B. Keogh (Birmingham, UK): Perhaps I could just say something about
where we are heading on the registry front. As you know, last year we
published a very slim and early version of an EACTS database report, which
will be slightly less slim this year in the sense that there will be more data in
from two additional countries. The strategy we had taken was that EACTS
would try and help individual nations collect their own data, because there
has to be ownership of that data, and probably the best way in the longer term
is to have that ownership at a national level and merging it at a supranational
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spread that out across the European Union, and within that grant, to include
at least one person for each of the contributing national societies. If it is an
EACTS-sponsored grant, we could explore what the job description of that
person.
Dr S. Hagl (Heidelberg, Germany): I fully support what Pieter just said,
but I think if we want to reach a real acceptable scientific level, it is not
sufficient to have only registries, to have studies. You also have to have the
instruments to control that these registries and these studies are really
getting valid data, and that is a difficult problem.
In Germany several registries have started. The outcome was highly
disappointing: only a part of procedures were registered, we didn’t know what
happened to the others, we had no instruments to control it. So what I wanted
to say is, it is not sufficient to have this only, but to have an instrument, an
apparatus behind it, which is really making out of such registries and out of
such data scientifically valuable information.
Mr Keogh: Siegfried (Siegfried Hagl), may I just bounce a proposal off
people? It is quite clear that as an Association we can’t afford the sort of
money that is required for the sort of solid scientific research and clinical
trials that you are talking about. The one thing that might be helpful, and we
could see what Bob (Robert Guezuraga) has to say about this, is we could put
out the message that EACTS might be interested, for example, in sponsoring or
kite-marking research, and that might encourage people who want to
undertake new research, albeit commercially funded or otherwise, to
approach the Association. If such a kite mark were to be applied it would
immediately give enormous credibility to any study that was proposed. But
the price that would have to be paid for that kite mark is intimate involvement
of, let’s say, a clinical trials group or a research committee in the design and,
most importantly, the analysis and publication of those results. And that way I
think we could have significant influence on how the research is conducted
without necessarily the financial commitment that would be needed to
conduct it on our own.
You may feel that that is not a good option. How would you respond to
something like that, Bob?
Mr R. Guezuraga (Minneapolis, Minnesota): I would be positive, and I
think industry would be positive. The basic research, research that leads to
product, and people don’t get very comfortable with this, but when industry
does research that leads to product, industry then wants the rights to that
product, or at least to share the rights for that product, because it’s going to
be commercialized, that would be sort of the general direction as to where
industry would want to do some funding.
Mr Keogh: We would be more interested in ensuring scientific integrity of
the study.
Mr Guezuraga: In the sense that you want to have something published,
and this happens all the time, the right to publish belongs to the person whodid the work. Now, I wouldn’t want to fund externally a technology that I have
a high level of interest in, and also, I would need to have a high level of
confidence that it was obviously going to turn out to the positive. But, if it
doesn’t, it doesn’t. We have funded studies, large-scale studies in Medtronic
businesses, that have produced poor results, and we just move on as a
consequence of it. Hopefully, it is an investment; it is not just throwing out
money.
Mr Keogh: How much value commercially is sponsorship from an
organization of this size to a study that you might be conducting? Are you
interested in that or is it too big a risk?
Mr Guezuraga: I will give you an example of a study. It would be in the
area of atrial fibrillation. All the manufacturers have devices that ablate
tissue, but in the United States it is the only claim that can be made. So studies
have to be done that these are devices that can do cardiac ablation, and
therefore those are the claims that are marketed once those claims are
submitted to the regulatory body and then are approved. So that would be an
interesting study.
Dr Hagl: Bruce (Bruce Keogh), if I may, I would like to add another point, it
was already discussed, and that is the point when we start to introduce
innovation into the clinics. What we are doing at the moment, or let’s say if
we look in the past, it was more or less uncontrolled, as we know. Everybody
took an instrument or a new device created by the industry and implanted it
and we never got results and exact and valid information how this new device
is really performing under clinical conditions. So I think it would be a very
important task for the European Association to control that in the future,
perhaps in cooperation with industry so that we get real information about
what happens and in what respect we can trust a new device. And it is not
sufficient, I say it again, it is not sufficient to have a registry, because nobody
is controlling that.
Dr von Segesser: So you are saying that we need an auditing body that
checks out what has been documented?
Dr Hagl: I think we can forget about all the studies, all the registries if we
are not consequently really controlling what happens, because I believe
nobody in that respect.
Dr von Segesser: So one of the ideas would be to establish an auditing
body like, for instance, the cancer people have. They have an organization;
you can organize a study, they bring in the study nurses. Of course, it costs
something. But I am not so sure about the statement that the EACTS cannot
afford something like that, because if you need 10,000 patients to show that
your approach is marginally better than the other one, it means that there is
no difference, and there are still topics around where you can do something
with 100 or 200 patients, and I think small trials, to start with, EACTS could
support.
Mr Keogh: That just highlights the need for clinical trials or an equivalent
group to start thinking about these things, doesn’t it?
